Clinical Trial Update: Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating induction therapy with vemurafenib and cobimetinib to optimize subsequent nivolumab and ipilimumab therapy in melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Melanoma, Malignant, of Soft Parts | Phase 2 | Status: UNKNOWN